KRAS and familial pancreatic carcinoma: While our future studies will address this possibility experimentally, it is important to note that 90–95% of pancreatic cancers have a KRAS mutation (65), which makes them intrinsically more permissive to VSV and other OVs via KRASMUT-mediated inhibition of antiviral signaling.